# A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

> **NCT06744205** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 1162 (actual)

## Conditions studied

- Influenza
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
- **BIOLOGICAL:** TIV mRNA-neuraminidase (NA)
- **BIOLOGICAL:** TIV mRNA-HA Vaccine 2
- **BIOLOGICAL:** Quadrivalent Influenza Standard Dose Vaccine
- **BIOLOGICAL:** Quadrivalent Influenza Vaccine High Dose

## Key facts

- **NCT ID:** NCT06744205
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-06
- **Primary completion:** 2026-04-16
- **Final completion:** 2026-04-16
- **Target enrollment:** 1162 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06744205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06744205, "A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06744205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*